Omnicell (NASDAQ:OMCL) Q3 2026 Results Exceed Guidance; Raises Profitability Outlook

Sonal Goyal

30 October 2026 09:45 PM AEDT

Omnicell (NASDAQ:OMCL) Q3 2026 Results Exceed Guidance; Raises Profitability Outlook

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Q3 2026 total revenues of $308 million exceeded the top end of guidance, marginally below prior year
GAAP Net Income of $11 million, or $0.24 per diluted share, more than doubled from $5 million in Q3 2025
Non-GAAP EBITDA of $45 million in Q3 2026 compared to $41 million in Q3 2025
Company raises full-year 2026 non-GAAP EBITDA and non-GAAP EPS guidance ranges

Revenue and Profit Beat Top End of Guidance

Omnicell, Inc. (NASDAQ:OMCL), a healthcare technology company focused on advancing autonomous medication management, reported total revenues of $308 million for the third quarter ended September 30, 2026. This was down $3 million, or 1%, from the third quarter of 2025, but came in above the high end of the company's previously provided guidance range. Continued Demand for Omnicell's connected device portfolio and disciplined cost management drove the outperformance.

GAAP net income for Q3 2026 was $11 million, or $0.24 per diluted share, compared to GAAP net income of $5 million, or $0.12 per diluted share, in Q3 2025. Non-GAAP net income was $27 million, or $0.58 per diluted share, compared to $24 million, or $0.51 per diluted share, in the prior year period. Non-GAAP EBITDA for the quarter was $45 million, compared to $41 million in Q3 2025.

Balance Sheet and Cash Flow

As of September 30, 2026, Omnicell's Balance Sheet reflected cash and cash equivalents of $315 million, total Debt net of unamortized issuance costs of $169 million, and total Assets of $2.1 billion. Cash flows provided by Operating Activities in Q3 2026 totaled $33 million, compared to $28 million in Q3 2025.

The company maintained $350 million of availability under its revolving Credit Facility with no outstanding balance, providing significant financial flexibility for operations and strategic investments. The cash position, in combination with credit availability, supports Omnicell's ability to invest in its next-generation platform.

Next-Generation Platform Gains Traction

Omnicell highlighted continued momentum in its next-generation autonomous medication management platform, centered on Titan XT hardware and OmniSphere, its cloud-native software platform. Customer validation of the combined Titan XT and OmniSphere solution is growing, with healthcare providers prioritizing operational efficiency and workforce productivity. Management noted a strong pipeline for the platform and indicated that it positions Omnicell to capture a significant long-term opportunity in autonomous medication management.

The company hosted its sixth annual Illuminate event, a virtual education and best practice-sharing forum that drew more than 200 healthcare leaders and industry experts. Topics included intelligent medication management strategies designed to improve clinical, operational, and financial outcomes. Omnicell also issued its 2025 Environmental, Social, and Governance report, reflecting its ongoing commitment to sustainability.

Guidance Updated for Full Year 2026

Based on the Q3 outperformance, Omnicell raised its full-year 2026 non-GAAP EBITDA guidance range and non-GAAP Earnings Per Share guidance range. The company also tightened its full-year 2026 total, product, and service Revenue guidance ranges as visibility improved heading into the final quarter. Full-year total revenues are now expected in the range of $1.225 billion to $1.231 billion.

For Q4 2026, Omnicell guided for total revenues of $295 million to $301 million, product revenues of $161 million to $164 million, and service revenues of $134 million to $137 million. Non-GAAP EBITDA for Q4 2026 is expected to be $30 million to $36 million. Annual Recurring Revenue for the full year was narrowed with the low end unchanged, reflecting improved visibility into the business.

Omnicell's third quarter demonstrated that its medication management solutions continue to find receptive customers in a healthcare environment focused on efficiency and workforce challenges. While total revenue was marginally below the prior year, the profitability improvement and above-guidance performance signal operational discipline. The rollout of Titan XT and OmniSphere will be central to the company's growth narrative in coming years.

How did Omnicell's Q3 2026 results compare to guidance?

Both revenue and profitability came in above the high end of Omnicell's previously provided guidance ranges for Q3 2026, reflecting strong execution and disciplined cost management.

What is Omnicell's full-year 2026 revenue guidance?

Full-year 2026 total revenues are expected to be in the range of $1.225 billion to $1.231 billion, with guidance ranges tightened from prior periods.

What is Omnicell's next-generation medication management platform?

Omnicell's next-generation platform centers on the Titan XT connected device and OmniSphere, a cloud-native software solution. Together, they are designed to improve productivity, workflow reliability, and visibility across medication management for healthcare providers.

How did Omnicell's non-GAAP EBITDA compare year-over-year in Q3 2026?

Non-GAAP EBITDA was $45 million in Q3 2026, up from $41 million in Q3 2025, reflecting the improvement in profitability from disciplined cost management and favorable margins.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.